Lastet 100 mg/5 ml (IV Infusion)
100 mg vial: ৳ 404.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Etoposide |
| Company | Nippon kayaku ltd |
Title
- Lastet
Categories
- Medicine
- Pharmaceuticals
- Cancer Treatment
Description
- Etoposide is indicated in the management of Small Cell Lung Cancer in combination with other approved chemotherapeutic agents as first-line treatment in patients with small cell lung cancer.
Therapeutic Class
- Cytotoxic Chemotherapy
Indications
- Management of Small Cell Lung Cancer
Mode of Action
- Pharmacotherapeutic classification: Podophyllotoxin derivatives
- Inhibition of mitosis by blocking microtubular assembly
- Inhibition of cell cycle progression at a premitotic phase (late S and G2)
- No interference with the synthesis of nucleic acids
Pharmacodynamics
- Inhibits mitosis by blocking microtubular assembly
Pharmacokinetics
- Biphasic process of disposition
- Distribution half-life of about 1.5 hours
- Terminal elimination half-life ranging from 4 to 11 hours
- Total body clearance values range from 33 to 48 ml/min
- Independence of clearance values from dose
- Linear increase in AUC and Cmax with dose
- No accumulation in plasma following daily administration
Dosage & Administration
- Dose ranges from 35 mg/m^2/day for 4 days to 50 mg/m^2/day for 5 days
- Initial dose modification based on measured creatinine clearance
Interaction
- Increased exposure and decreased clearance when combined with high-dose cyclosporine A
Contraindications
- Hypersensitivity to Etoposide or any component of the formulation
Side Effects
- Dose-related myelosuppression
- Nausea and vomiting
- Hypotension
- Allergic reactions including anaphylactic-like reactions
- Reversible alopecia
- Gastrointestinal toxicities
- Hematologic Toxicity
- Hypertension and/or flushing
- Other infrequently reported adverse reactions
Pregnancy & Lactation
- Pregnancy category D
- Etoposide found in human milk
Precautions & Warnings
- Frequent observation for myelosuppression
- Dose limiting bone marrow suppression
- Possible occurrence of an anaphylactic reaction
- Termination of infusion and symptomatic treatment for anaphylactic-like reactions
- Caution and evaluation of need against risk of adverse reactions
Storage Conditions
- Storage under refrigeration 2°-8°C
- Stable for 24 months under refrigeration conditions
- Protection from light
- Proper handling and disposal procedure for anticancer drugs